Recent studies have examined how mast cells contribute to host defense and revealed links between these cells and diseases with inflammatory components [1] . Evidence that mast cells suppress immune responses has also emerged [2]. As hypothesized by Kalesnikoff and Galli [1], the diversity of functions attributed to mast cells suggests that this compartment comprises specialized subsets rather than a homogeneous population.
Introduction
Allergic inflammatory reactions can be either acute (type I) or delayed (type IV). Acute reactions are initiated by contact between allergen and IgE bound to receptor complexes expressed on basophils and mast cells, resulting in physiologic responses within seconds. In the respiratory tract, acute allergic reactions cause coughing, sneezing and congestion and, in rare cases, can result in anaphylaxis. Delayed allergic reactions are promoted by cells within the innate and adaptive immune systems, with symptoms appearing several hours after allergen is encountered. In the airway, delayed reactions drive asthma development as manifested by chronic airway inflammation that leads to airway obstruction, airway hyper-responsiveness and lung tissue remodeling. These responses compromise lung function and, in severe cases, can cause death. Helper T cells that secret IL-4, IL-5 and IL-13, together with mast cells and basophils, are the dominant players in chronic allergic inflammation. Substantial progress has been made in defining the intracellular signaling pathways that regulate these cell types, with the goal being to define molecular targets for compounds that can be used as therapeutics for allergic inflammation. Here, we summarize recent findings regarding how mast cells and basophils contribute to allergic inflammation and discuss recent progress in characterizing signaling pathways that regulate these cells. We also highlight findings from studies that address how protein tyrosine kinases regulate T cell development and function and discuss the prospect of inhibiting these enzymes as a means to suppress allergic inflammation.
Mast cells and basophils in allergic inflammation
Purpose of review Activated mast cells, basophils, and CD4 þ helper T cells have critical roles in allergic inflammation. Therefore, devising ways to specifically inhibit these cells will likely be useful for controlling allergic inflammation. We summarize recent findings regarding the role of mast cells and basophils in allergic responses and the regulation of signaling pathways downstream of the IgE receptor, the chief inducer of mast cell and basophil activation. We also highlight studies addressing the roles of the protein tyrosine kinases Zap-70 and Itk in immune system development and in the regulation of CD4 þ helper T cell responses.
Recent findings
Recent work has demonstrated that mast cell function is unexpectedly diverse and that basophils have a more prominent role in Th2-type immune responses than previously appreciated. Biochemical analysis of the IgE receptor signaling pathway has led to insights regarding the roles of phosphatases and other enzymes in this process. Studies of Zap-70 and Itk have helped to define the potential outcomes and complications of inhibiting these enzymes in order to suppress allergic inflammation. Summary Analysis of genetically engineered mice and biochemical studies continue to help unravel the molecular pathways that drive allergic inflammatory reactions. The knowledge acquired may lead to novel approaches for suppressing allergic inflammation.
Mast cells are derived bone marrow progenitors and enter the bloodstream in an immature form. These cells migrate through blood vessel endothelium and localize to vascularized connective tissue beneath epithelial layers, including those that form the skin and line the digestive and respiratory tracts. Progenitors then differentiate into cells capable of effector function; these express the high-affinity FceR1, which constitutively binds IgE. Interaction between receptor-bound IgE and antigen results in mast cell activation and the release of multiple inflammatory mediators. Via this mechanism, mast cells initiate and amplify acute allergic inflammation and also contribute to chronic allergic responses. The latter role was further defined by recent studies showing that mast cells indirectly supply antigen for presentation to CD4 þ T cells and can provide costimulatory signals to these cells [3, 4 ] .
Basophils are derived from bone marrow progenitors and enter the blood as mature cells. Circulating basophils enter peripheral tissues in response to inflammation and promote the late phase of acute allergic reactions. Like mast cells, basophils express the FceR1 and are activated by antigen-induced aggregation of the receptor. Basophils can also be stimulated by various cytokines [5] . For example, recent studies [6] [7] [8] [9] [10] [11] [12] showed that IL-33 produced by epithelial cells and other cell types activates basophils as well as mast cells. Sokol et al. [13 ] demonstrated that the protease allergen papain elicits basophil activation, inducing their migration to draining lymph nodes and thus causing enhanced Th2 differentiation by CD4 þ T cells. These results suggest that basophils participate in immune responses to protease allergens, which have a significant role in human allergic disease.
Emerging data suggest that basophils have greater influence on adaptive Th2 responses than previously thought [5, 14] . Denzel et al. [15 ] showed that, upon secondary exposure to antigen, basophils activated via FceR1 engagement augment immunoglobulin production by interacting with B cells and providing IL-4 and IL-6. These data indicate that basophils have a role in memory humoral immune responses. Three publications collectively demonstrated that basophils present peptidemajor histocompatibility complex (MHC) II complexes to CD4 þ T cells while secreting IL-4, thus initiating Th2 cell differentiation [16 -18 ] . These data suggest that antigen presentation by basophils has a key role in the generation of allergen-specific Th2 cells in humans. It will be important to determine whether basophils present antigen to memory Th2 cells, which likely drive chronic allergic responses. Charles et al. [19 ] demonstrated that the absence of Lyn, which has a key role in suppression of FceR1 signaling, causes basophilia and strong skewing toward Th2-type responses. These studies support the hypothesis that targeted suppression of FceR1 signaling could be effective for controlling chronic, as well as acute, allergic inflammation. Overall, these findings indicate that further characterization of basophil function will reveal novel strategies for suppressing allergic disease.
New insights regarding the IgE receptor signaling pathway
Interaction between FceR1-bound IgE and antigen induces an elaborate network of signaling pathways that elicits cell activation (Fig. 1 ). The FceR1 consists of an IgE-binding a chain, a b chain and a disulfide-linked g chain homodimer. The cytoplasmic tails of the b and g subunits each contain immunoreceptor tyrosine-based activation motifs (ITAMs), which are targets for Src and Syk family protein tyrosine kinases. FceR1 engagement activates the Src family kinases (SFKs) Fyn and Lyn by an undefined mechanism, leading to ITAM phosphorylation and thus the generation of high-affinity docking sites for proteins that contain SH2 domains. These include Fyn, Lyn and the protein tyrosine kinase Syk. All three likely bind the phosphorylated ITAMs, promoting trans and auto-phosphorylation events that increase kinase activity and result in the tyrosine phosphorylation of multiple downstream substrates. Chief among these are the proteins LAT and LAT2 (LAB/ NTAL), which are phosphorylated on several tyrosines and thus associate with multiple SH2 domain-containing proteins. These include the adapter proteins SLP-76, Grb2, Gab2 and Gads and the GTP exchange factors SOS and Vav [2, 20] . The latter two proteins activate Ras, which induces mitogen-activated protein kinase (MAPK) signaling cascades. SOS, Vav and Gab2 also promote activation of PI3-kinase, which generates membranedocking sites for proteins containing pleckstrin homology domains. These include the key enzyme PLCg, which associates with the membrane and LAT/LAT2-containing complexes and becomes activated via tyrosine phosphorylation, generating second messenger molecules that induce calcium flux and protein kinase C activity. These events, combined with signals provided by MAPK cascades, induce the multiple events associated with mast cell and basophil activation.
Given their critical roles in FceR1 signaling, the protein tyrosine kinases Fyn, Lyn and Syk continue to be the focus of intense investigation and are discussed in recently published reviews [21, 22] . The central role of Syk in promoting FceR1 signaling has made this molecule a predominant target for molecular inhibitors. However, recent studies have implicated Syk in neutrophil function and phagocytosis [23, 24 ] , whereas others have demonstrated that Syk is important for mechanisms that detect fungal infections [25 ,26 ] . These findings emphasize the need to assess how targeted inhibition of Syk affects immune responses to microorganisms. Such studies will help determine whether molecules that inhibit Syk function can suppress allergic inflammatory responses without impairing host defense.
Recent studies have illustrated how protein tyrosine phosphatases regulate FceR1 signaling. Grochowy et al. [27] re-examined the role of the phosphatase CD45 using mouse bone marrow-derived mast cells (BMMCs). Lack of CD45 dramatically reduced degranulation, calcium flux and IL-6 production, which correlated with increased inhibitory phosphorylation of Lyn. Reciprocally, a hyperactive variant of CD45 increased FceR1 signaling, but surprisingly, failed to rescue Lyn from increased inhibition. Instead, greater PI3-kinase activity was observed, likely due to increased Fyn activation. These results support the proposal by Weiss and colleagues [28] that CD45 inhibition could be effective for controlling allergic disease. Akimoto et al. [29] showed that protein tyrosine phosphatase epsilon (PTPe) negatively regulates FceR1 signaling by suppressing Syk activation. Consistent with this conclusion, the responses of PTPe-deficient mice to anaphylactic challenge were exaggerated. Motheaten mice lack the tyrosine phosphatase SHP-1 and spontaneously develop immunodeficiency and autoimmunity. Nakata et al. [30] demonstrated that the absence SHP-1 increased phosphorylation of LAT and SLP-76 and MAPK activation but did not affect the upstream regulator Syk. Paradoxically, PLCg activation and calcium flux were impaired, suggesting that the adaptor function by SHP-1 is important or that SHP-1 functions to counteract inhibitory pathways. McPherson et al. [31] assessed the role of the tyrosine phosphatase SHP-2 in FceR1 signaling. Although degranulation by SHP-2-deficient cells was normal, the level of inhibitory Fyn phosphorylation was increased and correlated with reduced activation of the downstream Fyn targets Gab2 and PI3kinase. In contrast, the levels of inhibitory and activating phosphorylation of Lyn were normal and increased, respectively. These results suggest that SHP-2 has a role in maintaining the balance between Fyn and Lyn activity. Such regulation is likely important given the dual activating and inhibitory roles of Lyn [21] .
FceR1 signaling activates PI3-kinase, which generates phosphatidylinositol 1,4,5-triphosphate (PIP3) and thus membrane docking sites for other signaling proteins [32] . PIP3 is converted to PIP2 by the inositol phosphatases SHIP-1, SHIP-2 and PTEN, resulting in down-regulation of signaling. To assess the role of these proteins in FceR1 signaling, RNA interference was employed by different groups to knockdown expression of SHIP-1, SHIP-2 or PTEN. It was previously shown that the absence of SHIP-1 increases FceR1 signaling and cell activation [33] . Langdon et al. [34] extended these results by showing that knocking down SHIP-1 in bone marrowderived human basophils caused greater release of inflammatory mediators upon FceR1 engagement. Leung and Bolland [35] showed that knockdown of SHIP-2 in mouse BMMCs augments degranulation and microtubule formation while increasing transcription of IL-4 and IL-13 RNA. These effects correlated with increased activation of the PIP3-dependent kinase Akt and the small GTPase Rac-1, which both regulate microtubule assembly. Saini et al. [36] reported that SHIP-2 expression is significantly lower in peripheral blood mast cells from chronic idiopathic urticaria (CIU) patients, which correlated with higher levels of Syk and increased spontaneous histamine release. Furumoto et al. [37] showed that PTEN knockdown in human mast cells increases calcium flux and Akt activation and elicits spontaneous IL-8 and granulocyte macrophage colonystimulating factor (GM-CSF) secretion. Taken together, these studies indicate that SHIP-1, SHIP-2 and PTEN are all negative regulators of FceR1 signaling and suggest that strategies for augmenting inositol phosphatase activity could be effective for treating allergic inflammatory reactions.
CD4 R T cells and chronic allergic inflammation
Responses by CD4 þ T cells have a central role in chronic allergic inflammatory responses. Upon engagement of the TCR by peptide-MHC II complexes, naïve CD4 þ T cells proliferate and differentiate into effector cells that can be classified into four groups: Th1 cells that produce interferon-g (IFNg); Th2 cells, which generate IL-4, IL-5, IL-13 and IL-25; Th17 cells that secrete IL-17A, IL-17F, IL-21 and IL-22; and T regulatory (Treg) cells, which produce suppressive cytokines. Additional effector CD4 þ T cell subsets, such as Th9 and T follicular helper cells, have recently been described [38, 39] , suggesting that the biology of CD4 þ T cells is more complex than previously thought. Nevertheless, there is abundant evidence that Th2 cells have a central role in chronic allergic inflammatory disease [40] . For example, assessment of asthma patients has shown that airway infiltration by Th2-type CD4 þ T cells is a prominent feature of allergic airway inflammation [41] . Yet, it is becoming increasingly apparent that Th17 and Treg cells among others influence immune responses in the lung [38, 42, 43] . Thus, manipulation of these cells may prove useful for controlling asthma and other diseases.
The T cell receptor signaling pathway
The signaling pathways downstream of the TCR [44] and the FceR1 are similar in many respects. The TCR consists of antigen-specific a and b chains associated with CD4 and the CD3 complex (Fig. 2) . Receptor engagement induces phosphorylation of ITAMs in the cytoplasmic tails of CD3z subunits by the SFK Lck, resulting in recruitment of the Syk family kinase Zap-70. Crossphosphorylation and auto-phosphorylation upregulate Zap-70 kinase activity, which, together with Lck and the Tec kinase Itk, mediates phosphorylation of LAT and SLP-76. As in the FceR1 signaling pathway, LAT and SLP-76 support the formation of a complex containing PLCg1. The resulting increases in calcium flux and MAPK activity induced by PLCg1 and other pathways lead to the induction of multiple transcription factors and changes in cytoskeletal structure associated with T cell activation. Notably, the Tec family kinase Itk functions to phosphorylate PLCg1 and thus amplifies calcium flux and ERK MAPK activation.
T cell protein tyrosine kinases and allergic inflammation
The critical roles of protein tyrosine kinases in the TCR signaling pathway makes these enzymes attractive targets for inhibitors that could be used to suppress chronic allergic inflammatory responses. In this regard, Zap-70 and Itk have received the most attention with recent studies underscoring the complex role that each kinase plays in immune system development and in CD4 þ T cell responses.
Zap-70 is required for normal T cell development in both mice and humans [45] . Structural analysis by Deindl et al. [46] showed that Zap-70 is auto-inhibited by a mechanism involving intramolecular interactions. Stabilizing this arrangement with a small molecule could be an effective way to suppress Zap-70 activity. To date, no small molecule inhibitors of Zap-70 have been reported. Zap-70 contains tyrosine residues that have been implicated in both negative regulation and interactions with other proteins that promote TCR signaling. Hsu et al. the function of Zap-70 was compromised. These mice developed rheumatoid factor (i.e. antibodies for IgG) but not overt autoimmune disease. Siggs et al. [48] characterized mice expressing two different Zap-70 variants, each functionally impaired due to an amino acid substitution. Zap-70 mutant mice developed hyperglobulinemia and autoantibodies and responded poorly to foreign antigen. The data reported by Hsu et al. and Siggs et al. suggest that inhibiting Zap-70 beyond a certain threshold could lead to autoimmune responses and compromised host defense. However, both studies found that decreased Zap-70 function affected thymic T cell development, suggesting that the autoimmune responses observed could be due to defects in negative selection or Treg development. In contrast to these data, Picard et al. [49] reported that signs of autoimmunity were absent in an immunodeficient patient expressing a form of Zap-70 with reduced function. Guided by structural data, Levin et al. [50 ] generated Zap-70 variants that retain normal kinase activity but are sensitive to a small molecule inhibitor. Mice expressing these Zap-70 variants instead of the normal protein would be predicted to undergo normal T cell development. If so, such mice will be a useful tool for determining how pharmacological inhibition of Zap-70 affects the function of the mature immune system.
Itk represents an intriguing target for inhibitors that could be used to treat chronic allergic inflammation. Indeed, several studies have provided evidence that Itk is crucial for the responses of effector Th2 cells to secondary stimulation [51] . In contrast, the responses of Th1 effector cells to such secondary challenge are less affected, likely due to expression of the functionally redundant Tec kinase Rlk in Th1 cells. Gomez-Rodriguez et al. [52] recently reported that the absence of Itk expression decreased the ability of Th17-differentiated cells to produce IL-17A, but had no effect on the synthesis of other Th17 cytokines. These data suggest that the impact of inhibiting Itk on CD4 þ T cell function may extend beyond the Th2 subset.
As demonstrated by analysis of gene-deficient mice, Itk is not absolutely required for the development of T cells or other immune cell types [53] . Interestingly, Itk-deficient mice have reduced responses when tested using a model of allergic airway inflammation [54] . Ferrara et al. [55] recently showed that this phenotype correlates with reduced airway hyper-responsiveness. Yet, interpretation of data obtained from such studies is complicated by the fact that multiple aspects of immune system development are perturbed in Itk-deficient mice [53] . Two recent studies demonstrated that the gd T cell compartment in Itk-deficient mice is expanded and that these cells are required for the increased serum IgE levels seen in Itk-deficient mice [56 ,57 ] . This latter effect may have a negative impact on mast cell function, since the responses of Itk-deficient mice to allergen/IgE challenge are decreased [58] . These studies suggest that mice in which Itk expression can be ablated in a lineage-specific manner would be very helpful for clarifying what defects in Itk-deficient mice are responsible for the reduced responses to experimental asthma challenge. In addition, the approach taken with Zap-70, that is creation of an Itk variant that is sensitive to a specific inhibitor, would likely be useful for defining the impact of Itk inhibition on the function of the mature immune system in the absence of pre-existing developmental defects.
Conclusion
That mast cells and basophils have important roles in allergic inflammatory responses and that the FceR1 signaling pathway is a critical inducer of these cells is well established. Further, there is strong evidence that Th2type CD4þ T cells are the driving force behind chronic allergic inflammatory reactions. More detailed knowledge of the molecular pathways that regulate the functions of these cells will facilitate the development of novel and more specific inhibitors of allergic inflammation, for which there is a critical need. The studies described here help illustrate the complexity of this task but also provide hope that such inhibitors can be developed.
